FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118188575> ?p ?o ?g. }

• W3118188575 abstract "Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) can reduce oedema, improve vision and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO.The 2014 update of this review found high-quality evidence of benefit with anti-VEGF modalities, compared to laser photocoagulation, for the treatment of DMO. The objective of this updated review is to compare the effectiveness and safety of the different anti-VEGF drugs using network meta-analysis methods.We searched various electronic databases on 26 April 2017.We included randomised controlled trials (RCTs) that compared any anti-angiogenic drug with an anti-VEGF mechanism of action versus another anti-VEGF drug, another treatment, sham or no treatment in people with DMO.We used standard Cochrane methods for pair-wise meta-analysis and we augmented this evidence using network meta-analysis methods. We focused on the relative efficacy and safety of the three most commonly used drugs as interventions of direct interest for practice: aflibercept and ranibizumab, used on-label; and off-label bevacizumab.We collected data on three efficacy outcomes (gain of 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters; mean change in best-corrected visual acuity (BCVA); mean change in central retinal thickness (CRT)), three safety outcomes (all severe systemic adverse events (SSAEs); all-cause death; arterial thromboembolic events) and quality of life.We used Stata 'network' meta-analysis package for all analyses. We investigated the risk of bias of mixed comparisons based on the variance contribution of each study, having assigned an overall risk of bias to each study.Twenty-four studies included 6007 participants with DMO and moderate vision loss, of which two studies randomised 265 eyes of 230 participants and one was a cross-over study on 56 participants (62 eyes) that was treated as a parallel-arm trial. Data were collected on drugs of direct interest from three studies on aflibercept (975 eyes), eight studies on bevacizumab (515 eyes), and 14 studies on ranibizumab (1518 eyes). As treatments of indirect interest or legacy treatment we included three studies on pegaptanib (541 eyes), five studies on ranibizumab plus prompt laser (557 eyes), one study on ranibizumab plus deferred laser (188 eyes), 13 studies on laser photocoagulation (936 eyes) and six studies on sham treatment (793 eyes).Aflibercept, bevacizumab and ranibizumab were all more effective than laser for improving vision by 3 or more lines after one year (high-certainty evidence). Approximately one in 10 people improve vision with laser, and about three in 10 people improve with anti-VEGF treatment: risk ratio (RR) versus laser 3.66 (95% confidence interval (CI) 2.79 to 4.79) for aflibercept; RR 2.47 (95% CI 1.81 to 3.37) for bevacizumab; RR 2.76 (95% CI 2.12 to 3.59) for ranibizumab. On average there was no change in visual acuity (VA) with laser after one year, compared with a gain of 1 or 2 lines with anti-VEGF treatment: laser versus aflibercept mean difference (MD) -0.20 (95% CI -0.22 to -0.17) logMAR; versus bevacizumab MD -0.12 (95% CI -0.15 to -0.09) logMAR; versus ranibizumab MD -0.12 (95% CI -0.14 to -0.10) logMAR. The certainty of the evidence was high for the comparison of aflibercept and ranibizumab with laser and moderate for bevacizumab comparison with laser due to inconsistency between the indirect and direct evidence.People receiving ranibizumab were less likely to gain 3 or more lines of VA at one year compared with aflibercept: RR 0.75 (95% CI 0.60 to 0.94), moderate-certainty evidence. For every 1000 people treated with aflibercept, 92 fewer would gain 3 or more lines of VA at one year if treated with ranibizumab (22 to 148 fewer). On average people receiving ranibizumab had worse VA at one year (MD 0.08 logMAR units, 95% CI 0.05 to 0.11), moderate-certainty evidence; and higher CRT (MD 39 µm, 95% CI 2 µm to 76 µm; low-certainty evidence). Ranibizumab and bevacizumab were comparable with respect to aflibercept and did not differ in terms of VA: RR of gain of 3 or more lines of VA at one year 1.11 (95% CI 0.87 to 1.43), moderate-certainty evidence, and difference in change in VA was 0.00 (95% CI -0.02 to 0.03) logMAR, moderate-certainty evidence. CRT reduction favoured ranibizumab by -29 µm (95% CI -58 µm to -1 µm, low-certainty evidence). There was no evidence of overall statistical inconsistency in our analyses.The previous version of this review found moderate-certainty evidence of good safety of antiangiogenic drugs versus control. This update used data at the longest available follow-up (one or two years) and found that aflibercept, ranibizumab and bevacizumab do not differ regarding systemic serious adverse events (SSAEs) (moderate- or high-certainty evidence). However, risk of bias was variable, loop inconsistency could be found and estimates were not precise enough on relative safety regarding less frequent events such as arterial thromboembolic events or death (low- or very low-certainty evidence).Two-year data were available and reported in only four RCTs in this review. Most industry-sponsored studies were open-label after one year. One large publicly-funded study compared the three drugs at two years and found no difference.Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. Aflibercept may confer some advantage over ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms but it is unclear whether this applies to the long-term. There is a need for more evidence on the long-term (greater than two years) comparative effects of these anti-VEGF agents. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treated and under-monitored.We found no signals of differences in overall safety between the three antiangiogenic drugs that are currently available to treat DMO, but our estimates are imprecise for cardiovascular events and death." @default.
• W3118188575 created "2021-01-05" @default.
• W3118188575 creator A5015954067 @default.
• W3118188575 creator A5021233300 @default.
• W3118188575 creator A5022647583 @default.
• W3118188575 creator A5070694351 @default.
• W3118188575 creator A5091162454 @default.
• W3118188575 date "2018-10-16" @default.
• W3118188575 modified "2023-10-05" @default.
• W3118188575 title "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis" @default.
• W3118188575 cites W1481978003 @default.
• W3118188575 cites W1496977463 @default.
• W3118188575 cites W1526282761 @default.
• W3118188575 cites W1545259384 @default.
• W3118188575 cites W1559170621 @default.
• W3118188575 cites W1592641144 @default.
• W3118188575 cites W1782108791 @default.
• W3118188575 cites W1786299986 @default.
• W3118188575 cites W1811670323 @default.
• W3118188575 cites W1843322974 @default.
• W3118188575 cites W1851059930 @default.
• W3118188575 cites W1962920720 @default.
• W3118188575 cites W1968192671 @default.
• W3118188575 cites W1970858891 @default.
• W3118188575 cites W1972930110 @default.
• W3118188575 cites W1977305573 @default.
• W3118188575 cites W1977644809 @default.
• W3118188575 cites W1980342089 @default.
• W3118188575 cites W1980837668 @default.
• W3118188575 cites W1982179488 @default.
• W3118188575 cites W1982459755 @default.
• W3118188575 cites W1984387799 @default.
• W3118188575 cites W1987245350 @default.
• W3118188575 cites W1991120368 @default.
• W3118188575 cites W1993881088 @default.
• W3118188575 cites W1999957425 @default.
• W3118188575 cites W2001901310 @default.
• W3118188575 cites W2005486200 @default.
• W3118188575 cites W2009425569 @default.
• W3118188575 cites W2010599103 @default.
• W3118188575 cites W2014878084 @default.
• W3118188575 cites W2016795705 @default.
• W3118188575 cites W2022886290 @default.
• W3118188575 cites W2025420377 @default.
• W3118188575 cites W2029696545 @default.
• W3118188575 cites W2031573728 @default.
• W3118188575 cites W2033204635 @default.
• W3118188575 cites W2036712095 @default.
• W3118188575 cites W2037823415 @default.
• W3118188575 cites W2041706806 @default.
• W3118188575 cites W2044545140 @default.
• W3118188575 cites W2046402035 @default.
• W3118188575 cites W2046813533 @default.
• W3118188575 cites W2050020278 @default.
• W3118188575 cites W2051083561 @default.
• W3118188575 cites W2051937264 @default.
• W3118188575 cites W2054061193 @default.
• W3118188575 cites W2057983131 @default.
• W3118188575 cites W2059199034 @default.
• W3118188575 cites W2074147400 @default.
• W3118188575 cites W2079713841 @default.
• W3118188575 cites W2081777756 @default.
• W3118188575 cites W2084673333 @default.
• W3118188575 cites W2090132603 @default.
• W3118188575 cites W2091729420 @default.
• W3118188575 cites W2091808438 @default.
• W3118188575 cites W2102463203 @default.
• W3118188575 cites W2109563236 @default.
• W3118188575 cites W2111502329 @default.
• W3118188575 cites W2115756084 @default.
• W3118188575 cites W2116525177 @default.
• W3118188575 cites W2123123877 @default.
• W3118188575 cites W2123698501 @default.
• W3118188575 cites W2128701654 @default.
• W3118188575 cites W2129821518 @default.
• W3118188575 cites W2134048257 @default.
• W3118188575 cites W2138480916 @default.
• W3118188575 cites W2140018458 @default.
• W3118188575 cites W2143429362 @default.
• W3118188575 cites W2144625636 @default.
• W3118188575 cites W2156799887 @default.
• W3118188575 cites W2158769384 @default.
• W3118188575 cites W2160821049 @default.
• W3118188575 cites W2161279821 @default.
• W3118188575 cites W2161588304 @default.
• W3118188575 cites W2162309497 @default.
• W3118188575 cites W2162581351 @default.
• W3118188575 cites W2164855431 @default.
• W3118188575 cites W2169971427 @default.
• W3118188575 cites W2171946822 @default.
• W3118188575 cites W2188489962 @default.
• W3118188575 cites W2216901845 @default.
• W3118188575 cites W2216990732 @default.
• W3118188575 cites W2253123730 @default.
• W3118188575 cites W2289200040 @default.
• W3118188575 cites W2289847121 @default.
• W3118188575 cites W2318276210 @default.
• W3118188575 cites W2318393469 @default.
• W3118188575 cites W2321637412 @default.
• W3118188575 cites W2411898694 @default.

• next